MT1G and neoplasm: For example, Sun et al. found that metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis, and genetic and pharmacological suppression of metallothionein-1G promoted the anticancer activity of sorafenib in vitro and in xenogenetic tumor models [20].